Source link : https://newshealth.biz/health-news/combination-therapy-offers-confidence-to-ckdt2d-patients/
VIENNA — Combining the SGLT2 inhibitor empagliflozin with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), markedly and durably reduced albuminuria in patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D), the CONFIDENCE trial showed in findings that offer hope of a long-term improvement in outcomes. In the trial, 70% of patients on […]
The post Combination Therapy Offers CONFIDENCE to CKD+T2D Patients first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-05 19:59:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8